2 assets in Parathyroid Gland Carcinoma

Therapeutic assets addressing Parathyroid Gland Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Parathyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Parathyroid Gland Carcinoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)